Roche (OTCQX:RHHBY)
does a lot of things well. It is one of the largest players in oncology
and markets three of the top ten best-selling drugs in the world. It
also has a strong diagnostics business and a deep immuno-oncology
platform. What Roche has not done so well, though, is develop new drugs
outside of oncology, with notable recent failures in cardiology,
diabetes, and CNS disease. Given those failures, and perhaps seeing an
opportunity to leverage existing efforts in pulmonary/respiratory
disease, Roche has stepped up with an expensive bid for InterMune (NASDAQ:ITMN).
Read more here:
With An Iffy Non-Oncology Pipeline, Roche Pays Up For InterMune
No comments:
Post a Comment